Effects of Jiangzhi Baoganfang on the Metabolic Disorders of Glucose and Lipid in Type 2 Diabetic Rat with Hyperlipemia
MO Wei-hao
Abstract
MO Wei-hao
Abstract
Objective:To investigate the effects of Jiangzhi Baoganfang on the metabolic disorders of glucose and lipid in type 2 diabetic rat with hyperlipemia.Method: Type 2 diabetic rat model was established by high-fat diet with tail vein injection of streptozotocin(STZ,38 mg·kg-1).Model rats were randomly divided into model group,positive medicine group(metformin 0.18 g · kg-1),Jiangzhi Baoganfang group 9.54 g · kg-1 and normal control group.Then the rats were administered with corresponding drugs for 35 days.The fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL),high density lipoprotein(HDL),malondialdehyde(MDA),superoxide dismutase(SOD),as well as TC,TG,MDA and SOD in liver were measured.Result: Compared with model group,the levels of FPG,HbA1c in serum,TC,TG,LDL and MDA in serum and liver were significantly increased while the level of HDL and the activity of SOD in serum and liver were significantly decreased in model group(P0.05).The levels of FPG,HbA1c in serum,TC,TG,LDL and MDA in serum and liver were significantly reduced while the level of HDL and the activity of SOD in serum and liver was significantly higher in Jiangzhi Baoganfang group(P0.05).Conclusion: Jiangzhi Baoganfang can adjust the metabolic disorders of glucose and lipid in type 2 diabetic rat with hyperlipemia,decrease the lipid levels in liver and improve the antioxidant capacity.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To investigate the effects of Jiangzhi Baoganfang on the metabolic disorders of glucose and lipid in type 2 diabetic rat with hyperlipemia.Method: Type 2 diabetic rat model was established by high-fat diet with tail vein injection of streptozotocin(STZ,38 mg·kg-1).Model rats were randomly divided into model group,positive medicine group(metformin 0.18 g · kg-1),Jiangzhi Baoganfang group 9.54 g · kg-1 and normal control group.Then the rats were administered with corresponding drugs for 35 days.The fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL),high density lipoprotein(HDL),malondialdehyde(MDA),superoxide dismutase(SOD),as well as TC,TG,MDA and SOD in liver were measured.Result: Compared with model group,the levels of FPG,HbA1c in serum,TC,TG,LDL and MDA in serum and liver were significantly increased while the level of HDL and the activity of SOD in serum and liver were significantly decreased in model group(P0.05).The levels of FPG,HbA1c in serum,TC,TG,LDL and MDA in serum and liver were significantly reduced while the level of HDL and the activity of SOD in serum and liver was significantly higher in Jiangzhi Baoganfang group(P0.05).Conclusion: Jiangzhi Baoganfang can adjust the metabolic disorders of glucose and lipid in type 2 diabetic rat with hyperlipemia,decrease the lipid levels in liver and improve the antioxidant capacity.
Key concepts: Internal medicine, Malondialdehyde, Endocrinology, Triglyceride, Chemistry, Type 2 diabetes, Metformin, Superoxide dismutase